{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:50ddda6f-a8a3-4b13-bca3-b372d24ce1e6", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-09-30T15:04:58.294814Z", "firstcreated": "2026-09-30T15:00:59.644771Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "Tirzepatide Plus Eloralintide Yields 23% Weight Loss in Trial", "byline": "Harriet Beaumont", "located": "United Kingdom", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / The Bizzi Route", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "Combining tirzepatide with the experimental drug eloralintide produced substantially greater weight loss than tirzepatide alone in a phase 2 trial of adults with type 2 diabetes, though side effects and dropout rates were higher.", "altids": {"mosaic": "50ddda6f-a8a3-4b13-bca3-b372d24ce1e6", "story": "24be2244-872d-4236-894a-c43a94ec6208", "slug": "tirzepatide-plus-eloralintide-yields-23-weight-loss-in-trial"}, "subject": [{"name": "Technology", "rel": "direct", "literal": "technology", "code": "medtop:13000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/13000000"}], "place": [{"name": "United Kingdom", "literal": "gb", "code": "GB", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "Combining tirzepatide with the experimental drug eloralintide produced substantially greater weight loss than tirzepatide alone in a phase 2 trial of adults with type 2 diabetes, though side effects and dropout rates were higher.", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:6d4787b8-b809-4cae-bf00-fb1d4b1558ed", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "‘Astonishing’ weight loss when GLP-1 drug used with second medication", "description_text": "Tirzepatide Plus Eloralintide Yields 23% Weight Loss in Trial", "copyrightholder": "newscientist.com", "copyrightnotice": "‘Astonishing’ weight loss when GLP-1 drug used with second medication", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "6d4787b8-b809-4cae-bf00-fb1d4b1558ed"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-09-30T15:04:58.319664Z", "attribution_required": true, "attribution_text": "‘Astonishing’ weight loss when GLP-1 drug used with second medication", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "newscientist.com", "source_url": "https://www.newscientist.com/wp-content/uploads/2026/09/SEI_314688651.jpg", "source_page_url": "https://www.newscientist.com/wp-content/uploads/2026/09/SEI_314688651.jpg", "our_page_url": "https://thebizziroute.com/technology/tirzepatide-plus-eloralintide-yields-23-weight-loss-in-trial/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://www.newscientist.com/wp-content/uploads/2026/09/SEI_314688651.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:24be2244-872d-4236-894a-c43a94ec6208", "slug": "m-night-shyamalan-devoile-remain-a-beyond-fest-et-les-premieres-reactions-saluent-jake-gyllenhaal-20260930", "status": "updated", "languages": ["de", "en", "es", "fr", "uk"], "item_count": 7, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / The Bizzi Route", "canonical_required": true, "canonical_url": "https://thebizziroute.com/technology/tirzepatide-plus-eloralintide-yields-23-weight-loss-in-trial/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "multi_source", "independent_confirmations": 1, "official_source_used": false, "used_press_release": false, "public_interest": false, "ai_disclosure_required": false, "ai_disclosure_text": "", "independence_check": {"status": "failed", "score": 0.79, "checked_at": "2026-09-30T15:04:58.315919Z"}}, "wireva:publication": {"name": "The Bizzi Route", "domain": "thebizziroute.com", "country": "GB", "url": "https://thebizziroute.com/technology/tirzepatide-plus-eloralintide-yields-23-weight-loss-in-trial/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/50ddda6f-a8a3-4b13-bca3-b372d24ce1e6", "html": "https://wireva.mib.news/item/50ddda6f-a8a3-4b13-bca3-b372d24ce1e6/tirzepatide-plus-eloralintide-yields-23-weight-loss-in-trial/", "story": "https://wireva.mib.news/story/m-night-shyamalan-devoile-remain-a-beyond-fest-et-les-premieres-reactions-saluent-jake-gyllenhaal-20260930/"}, "wireva:metrics": {"word_count": 649, "char_count": 4172, "reading_time_seconds": 298}}}